- Mechanisms of SGLT2 protein inhibition2015 | Third Faculty of Medicine
- Empagliflozin - new SGLT2 inhibitor for diabetes mellitus treatment2014 | Third Faculty of Medicine, First Faculty of Medicine
- Current use of SGLT2 inhibitors in type 2 diabetes mellitus2016 | First Faculty of Medicine
- New mechanism of treatment DM: glifloziny, SGLT2 inhibitors2014 | Second Faculty of Medicine
- Empagliflozin and current position SGLT2 inhibitors in the treatment of type 2 diabetes2015 | First Faculty of Medicine
- Glucuretics (SGLT2 inhibitors, gliflosine) in the treatment of diabetes2011 | Third Faculty of Medicine
- Canagliflozin: clinical significance of simultaneous balanced influencing of SGLT2 and SGLT12015 | Second Faculty of Medicine
- Renoprotective effects of SGLT2 inhibitors - gliflozins2021 | First Faculty of Medicine
- Current position of SGLT2 inhibitors (gliflozins) in the treatment of diabetes mellitus2018 | Second Faculty of Medicine
- The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors2020 | Second Faculty of Medicine
- SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure2021 | First Faculty of Medicine
- Position of new antidiabetics in clinical practice: SGLT2 vs DPP4 inhibitors2015 | First Faculty of Medicine
- New treatment options for chronic kidney disease - focused on SGLT2 inhibitors2021 | First Faculty of Medicine
- The position of SGLT2 inhibitors in current medicine2020 | First Faculty of Medicine
- What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin?2022 | First Faculty of Medicine
- SGLT2 inhibitors in the treatment of type 1 diabetic patients2019 | First Faculty of Medicine
- Léčba diabetika inhibitory SGLT2 pro praxi2020 | First Faculty of Medicine
- Kardiovaskulární studie se SGLT2 inhibitory: čím se liší a co mají společného?2019 | First Faculty of Medicine
- Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type2015 | Third Faculty of Medicine, First Faculty of Medicine
- The position of SGLT2 inhibitors in current medical practice - update 20222022 | First Faculty of Medicine
- Volba mezi inhibitory DPP4 a SGLT2 u diabetiků 2. typu nekompenzovaných na metforminu2018 | Second Faculty of Medicine
- Dapagliflozin and its position in DM 2 treatment2017 | Faculty of Medicine in Pilsen
- Canagliflozin reduces the risk of CKD progression in type 2 diabetes with nephropathy - main results of the CREDENCE study2019 | First Faculty of Medicine
- SGLT2 inhibitors in T2D and associated comorbidities differentiating within the class2019 | First Faculty of Medicine
- Dapagliflozin: aspects of clinical use2014 | Second Faculty of Medicine
- Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases +12022 | Third Faculty of Medicine, First Faculty of Medicine
- Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases +12022 | Third Faculty of Medicine, First Faculty of Medicine, Central Library of Charles University
- Inhibitory SGLT2 jsou renoprotektivní i u nediabetických onemocnění ledvin2021 | First Faculty of Medicine
